Join
Live feed
·
PRReleasevia Quantisnow
Oncternal Therapeutics Inc. logo

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ONCT· Oncternal Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ONCT (Oncternal Therapeutics Inc.) and more on Quantisnow.